Literature DB >> 1917385

Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells.

P L Lollini1, C De Giovanni, L Landuzzi, G Nicoletti, K Scotlandi, P Nanni.   

Abstract

We studied the human embryonal rhabdomyosarcoma cell line RD and 8 derivatives obtained in our laboratory either by cell cloning or by culturing in vitro cells from tumors or secondaries grown in nude mice. The expression of desmin and of the embryonic isoform of myosin and the formation of multinuclear myotube-like structures were studied as specific markers of myogenic differentiation. During continuous growth, each derivative contained a proportion (ranging from 5 to 80% among derivatives) of desmin-positive cells and a small number of myosin-positive or multinuclear elements. Cells from continuous cultures were injected intravenously in nude mice, producing lung and kidney/adrenal nodules. No correlation was found between the proportion of cells expressing desmin and metastatic capacity. When cultures were grown in differentiation medium (Dulbecco's minimal essential medium + 2% horse serum) some derivatives (designated type A) showed a strong increase in the proportion of myosin-positive cells, while others (type B) showed no increase. In vitro differentiation significantly reduced the metastatic ability of type A cells, while no modification was observed in type B after growth in differentiation medium. The proliferative ability of type A and type B cells grown in differentiation medium did not correlate with the proportion of myosin-positive cells, and extensive formation of multinuclear myotubes was never observed. It was concluded that reduction of experimental metastatic ability was mediated by events related to late, though not necessarily terminal, differentiation of rhabdomyosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917385

Source DB:  PubMed          Journal:  Invasion Metastasis        ISSN: 0251-1789


  16 in total

1.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

2.  Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.

Authors:  Silvia Codenotti; Maura Poli; Michela Asperti; Daniela Zizioli; Francesco Marampon; Alessandro Fanzani
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-03       Impact factor: 4.553

3.  JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Authors:  Z S Walters; B Villarejo-Balcells; D Olmos; T W S Buist; E Missiaglia; R Allen; B Al-Lazikani; M D Garrett; J Blagg; J Shipley
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

4.  MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Authors:  E Missiaglia; C J Shepherd; S Patel; K Thway; G Pierron; K Pritchard-Jones; M Renard; R Sciot; P Rao; O Oberlin; O Delattre; J Shipley
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

5.  Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading.

Authors:  Janine Berkholz; Weronika Kuzyniak; Michael Hoepfner; Barbara Munz
Journal:  Clin Exp Metastasis       Date:  2014-09-11       Impact factor: 5.150

6.  Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination.

Authors:  G Nicoletti; C De Giovanni; L Landuzzi; G Simone; P Rocchi; P Nanni; P L Lollini
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

7.  The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.

Authors:  Michel Schmitt-Ney; Giovanni Camussi
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

8.  MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.

Authors:  Fiorella Faggi; Silvia Codenotti; Pietro Luigi Poliani; Manuela Cominelli; Nicola Chiarelli; Marina Colombi; Marika Vezzoli; Eugenio Monti; Federica Bono; Giovanni Tulipano; Chiara Fiorentini; Alessandra Zanola; Harriet P Lo; Robert G Parton; Charles Keller; Alessandro Fanzani
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

9.  Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells.

Authors:  C De Giovanni; P L Lollini; R Dolcetti; L Landuzzi; G Nicoletti; E D'Andrea; K Scotland; P Nanni
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

10.  An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.

Authors:  Clara Guerzoni; Stefano Amatori; Luca Giorgi; Maria Cristina Manara; Lorena Landuzzi; Pier-Luigi Lollini; Aurora Tassoni; Mauro Balducci; Marco Manfrini; Loredana Pratelli; Massimo Serra; Piero Picci; Mauro Magnani; Vieri Fusi; Mirco Fanelli; Katia Scotlandi
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.